Botulinum neurotoxins: Mechanism of action

被引:72
作者
Tighe, Ann P.
Schiavo, Giampietro [1 ,2 ]
机构
[1] Canc Res UK London Res Inst, Mol Neuropathobiol Lab, Lincolns Inn Fields Labs, London WC2A 3LY, England
[2] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England
关键词
Botulinum neurotoxin; SNARE complex; Neuromuscular junction; Mechanism of action; Synaptic transmission; SNAP-25; TOXIN TYPE-A; CLOSTRIDIUM-BOTULINUM; STRUCTURAL-ANALYSIS; BINDING-SITES; SEROTYPE D; NEURONS; GANGLIOSIDE; SEQUENCE; RECEPTOR; IDENTIFICATION;
D O I
10.1016/j.toxicon.2012.11.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Botulinum neurotoxins are used clinically for conditions characterized by hyperexcitability of peripheral nerve terminals and hypersecretory syndromes. These neurotoxins are synthesized as precursor proteins with low activity, but their effects are mediated by the active form of the neurotoxin through a multistep mechanism. Following a high-affinity interaction with a protein receptor and polysialogangliosides on the synaptic membrane, botulinum neurotoxins enter the neuron and causes a sustained inhibition of synaptic transmission. The active neurotoxin is part of a high-molecular-weight complex that protects the neurotoxin from proteolytic degradation. Although complexing proteins do not affect diffusion of therapeutic neurotoxin, they may lead to the development of neutralizing antibodies that block responsiveness to it. Nerve terminal intoxication is reversible and its duration varies for different BoNT serotypes. Although it was previously assumed that botulinum neurotoxins exert effects only on the peripheral synapses, such as the neuromuscular junction, there is now substantial evidence that these neurotoxins affect neurotransmission at distal central nervous system sites as well. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 51 条
  • [31] Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides as Receptors
    Peng, Lisheng
    Tepp, William H.
    Johnson, Eric A.
    Dong, Min
    [J]. PLOS PATHOGENS, 2011, 7 (03):
  • [32] Poulain B., 2008, The Botulinum J, V1, P14, DOI DOI 10.1504/TBJ.2008.018951
  • [33] Restani L., PLOS PATHOG IN PRESS
  • [34] Evidence for Anterograde Transport and Transcytosis of Botulinum Neurotoxin A (BoNT/A)
    Restani, Laura
    Antonucci, Flavia
    Gianfranceschi, Laura
    Rossi, Chiara
    Rossetto, Ornella
    Caleo, Matteo
    [J]. JOURNAL OF NEUROSCIENCE, 2011, 31 (44) : 15650 - 15659
  • [35] Rossetto Ornella, 2008, V184, P129
  • [36] Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G
    Rummel, A
    Karnath, T
    Henke, T
    Bigalke, H
    Binz, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (29) : 30865 - 30870
  • [37] Neurotoxins affecting neuroexocytosis
    Schiavo, G
    Matteoli, M
    Montecucco, C
    [J]. PHYSIOLOGICAL REVIEWS, 2000, 80 (02) : 717 - 766
  • [38] Structural biology - Dangerous liaisons on neurons
    Schiavo, Giampietro
    [J]. NATURE, 2006, 444 (7122) : 1019 - 1020
  • [39] Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes
    Sebaihia, Mohammed
    Peck, Michael W.
    Minton, Nigel P.
    Thomson, Nicholas R.
    Holden, Matthew T. G.
    Mitchell, Wilfrid J.
    Carter, Andrew T.
    Bentley, Stephen D.
    Mason, David R.
    Crossman, Lisa
    Paul, Catherine J.
    Ivens, Alasdair
    Wells-Bennik, Marjon H. J.
    Davis, Ian J.
    Cerdeno-Tarraga, Ana M.
    Churcher, Carol
    Quail, Michael A.
    Chillingworth, Tracey
    Feltwell, Theresa
    Fraser, Audrey
    Goodhead, Ian
    Hance, Zahra
    Jagels, Kay
    Larke, Natasha
    Maddison, Mark
    Moule, Sharon
    Mungall, Karen
    Norbertczak, Halina
    Rabbinowitsch, Ester
    Sanders, Mandy
    Simmonds, Mark
    White, Brian
    Whithead, Sally
    Parkhill, Julian
    [J]. GENOME RESEARCH, 2007, 17 (07) : 1082 - 1092
  • [40] Sharma SK, 2000, J NAT TOXINS, V9, P357